A Randomized, Double-blind, Placebo-controlled, Mutiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IBI3033 in Healthy Participants
Latest Information Update: 12 Mar 2026
At a glance
- Drugs IBI 3033 (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Adverse reactions
- Sponsors Innovent Biologics
Most Recent Events
- 12 Mar 2026 New trial record